Effect of Metformin on Frailty in 12 Subjects

• Sponsor: Mayo Clinic (Other)
• Overall Status: Completed
• CT.gov ID: NCT03451006
• Collaborator: (none)
• Enrollment: 5
• Location: 1
• Arms: 2
• Actual Duration (Months): 42.8
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.

Condition or Disease	Intervention/Treatment	Phase
Aging; Inflammation; Frailty	Drug: Metformin; Drug: Placebo	Phase 2

Detailed Description

Heart disease is the number one cause of death in the United States and disproportionately affects older adults, underscoring the need to examine determinants of survivorship. Recognizing this gap, current guidelines lay emphasis to assess frailty, a key construct prevalent in elderly and known to impact their prognosis.Older persons are commonly frail, manifest hyperglycemia and their health span is truncated by illnesses during which physiological declines together with accumulation of additional deficits results in multimorbidity and functional dependence. High incidence of functional decline and stress hyperglycemia in patients with coronary artery disease (CAD) makes pharmacologic manipulation, an attractive strategy to improve frailty and reduce adverse cardiovascular outcomes. Metformin exerts its effect on health span as a calorie restriction-mimetic through inhibition of mitochondrial complex 1 and activation of activated protein kinase (AMP).This drug is safe and has been shown to prolong life in mammals. Metformin by reducing effects of cellular senescence and improving glycemic control may improve the functioning of older adults.

In CAD, cellular senescence and inflammation affect organ dysfunction through interference with tissue homeostasis and regeneration. The deleterious effect of senescence includes pro-inflammatory senescence-associated secretory phenotype (SASP). Normal biological function through alteration in cellular homeostasis and restoration of glycemic control may be achieved by metformin. The phenotypic manifestations of these changes are incompletely characterized as it is yet unknown whether cell-intrinsic regenerative mechanisms can be translated into clinical improvement in physical performance and whether it's chronic administration is safe in older adults. These major gaps in knowledge hinder utilization of metformin as an agent to promote cellular regeneration and to reduce the impact of cellular senescence.

Targeting frail individuals with high levels of inflammation and SASP factors would necessitate identification of predictors of improvement with metformin in tissue inflammation and function. A clinomics approach implementing simultaneous assessment of clinical impact coupled with serological profiling would provide enhanced understanding of the local and systemic impact mediated by metformin. Through correlation of molecular profiles with phenotypic expression changes, as proposed herein, investigators will enhance understanding of the regenerative impact of metformin and the basis for clinical improvement in the setting of senescence.

Study Design

• Study Type: Interventional
• Actual Enrollment: 5 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Arms Assigned interventions Placebo Comparator: Metformin Chronic metformin administration through augmentation of cellular regeneration and reduction of senescence will improve frailty and physical functioning as studied by the short physical performance battery (SPPB) test. Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score <9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months. Placebo comparator: Placebo Placebo will be compared to chronic metformin administration Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score <9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months.Arms Assigned interventions Placebo Comparator: Metformin Chronic metformin administration through augmentation of cellular regeneration and reduction of senescence will improve frailty and physical functioning as studied by the short physical performance battery (SPPB) test. Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score <9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months. Placebo comparator: Placebo Placebo will be compared to chronic metformin administration Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score <9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months.
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: (MATE) Metformin and Aging Trial in the Elderly: A Pilot and Feasibility Study
• Actual Study Start Date: May 24, 2018
• Actual Primary Completion Date: Dec 16, 2021
• Actual Study Completion Date: Dec 16, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Metformin Metformin 500mg tablet by mouth, every 6 to 8 hours for one year	Drug: Metformin; Oral metformin (up to 2gm) will be given in divided doses
Active Comparator: Placebo Placebo by mouth every 6 to 8 hours for one year	Drug: Placebo; Oral Placebo will be given in divided doses

Outcome Measures

Primary Outcome Measures

1. Change in frailty [Baseline, 12 months]

   Frailty will be measured by the Short Physical Performance Battery (SPPB). The short physical performance battery (SPPB) is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance). Frailty is defined as a score of <9.

2. Change in balance score standing with feet close together [Baseline, 12 months]

   This measure is part of the SPPB. The scores range from 0 (not attempted), to 2 (held for 10 seconds). Ability to stand longer in this position indicates greater balance.

3. Change in balance score standing in semi tandem position [Baseline, 12 months]

   This measure is part of the SPPB. The semi tandem position is the heel of one foot place by the big toe of the other foot. The scores range from 0 (not attempted), to 2 (held for 10 seconds). Ability to stand longer in this position indicates greater balance.

4. Change in balance score standing in full tandem position [Baseline, 12 months]

   This measure is part of the SPPB. The full tandem position is with the feet directly in front of each other. The scores range from 0 (not attempted), to 2 (held for 10 seconds). Ability to stand longer in this position indicates greater balance.

5. Change in gait speed [Baseline, 12 months]

   This measure is part of the SPPB. Subjects will be asked to walk 8 feet or 2.44 meters at their usual pace. They will be allowed to use a cane or other walking aid if it is their custom. Scores range from 0 = could not do to 4 =<3.1 seconds.

6. Change in score, standing test from chair [Baseline,12 months]

   This measure is part of the SPPB. Subjects will be asked to try to stand up from a chair 5 times with arms folded across their chest, and will be timed. Scores range from 0 to 4, with 0 = unable to stand without using arms, and 4 = completing 5 stands in <11.1 seconds.

Secondary Outcome Measures

1. Change in Interleukin 6 (pg/ml) [Baseline, 12 months]

   Serum will be collected to measure the effect of metformin on senescent markers.

2. Change in Matrix metalloproteinase (ng/ml) [Baseline, 12 months]

   Serum will be collected to measure the effect of metformin on senescent markers.

3. Change in Plasminogen activator inhibitor [Baseline, 12 months]

   Serum will be collected to measure the effect of metformin on senescent markers.

4. Change in Monocyte chemotactic protein-1 [Baseline, 12 months]

   Serum will be collected to measure the effect of metformin on senescent markers.

5. Change in Activin [Baseline, 12 months]

   Serum will be collected to measure the effect of metformin on senescent markers.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 60 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age ≥ 60 years

• Stable CAD

• Prediabetes (one of the following criteria should be met)

• Fasting plasma glucose: 100-126 mg/dL

• HbA1C: 5.7-6.4

• Frailty (Short Physical Performance Battery: Score <9)

• Able to return for follow-up

• Written informed consent

Exclusion criteria:

• Pre-existing or new-onset diabetes

• Any active malignancy, hematological disorder, post organ transplant, immunocompromised

• Cancer requiring treatment in the past 3 years (other than non-melanoma skin cancer)

• Dementia [mini mental state examination (MMSE <20)]

• Disability (need for assistance in >2 of any six activities on Katz activities of daily living (ADL)46

• Prior stroke with disability

• Acute coronary syndrome <3months or participating in cardiac rehabilitation

• Severe Parkinson's

• Hepatic insufficiency and/or chronic liver disease (cirrhosis)

• Chronic kidney disease (GFR < 45 mL/min)

• Taking metformin for any indication

• Acute alcohol intoxication

• Known hypersensitivity to metformin hydrochloride

• Acute/chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic in Rochester	Rochester	Minnesota	United States	55905

Sponsors and Collaborators

• Mayo Clinic

Investigators

• Principal Investigator: Mandeep Singh, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Mayo Clinic Clinical Trials

Publications

None provided.

• Responsible Party: Mandeep Singh, Professor of Medicine, Mayo Clinic
• ClinicalTrials.gov Identifier: NCT03451006
• Other Study ID Numbers: 17-003088
• First Posted: Mar 1, 2018
• Last Update Posted: Feb 3, 2022
• Last Verified: Feb 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Additional relevant MeSH terms: Inflammation; Frailty; Metformin

Study Results

No Results Posted as of Feb 3, 2022